{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:14:22Z","timestamp":1793042062832,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jcpo.2024.100476","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T21:55:44Z","timestamp":1712440544000},"page":"100476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas"],"prefix":"10.1016","volume":"40","author":[{"given":"Miguel","family":"Zugman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-8221","authenticated-orcid":false,"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9490","key":"10.1016\/j.jcpo.2024.100476_bib1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcpo.2024.100476_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2019.04.027","article-title":"Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma","volume":"137","author":"Tabrizi","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.jcpo.2024.100476_bib3","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","author":"Bent","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jcpo.2024.100476_bib4","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2024.100476_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10917-z","article-title":"Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020","volume":"23","author":"Olivier","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jcpo.2024.100476_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-023-07412-y","article-title":"Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use","volume":"24","author":"Prasad","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.jcpo.2024.100476_bib7","doi-asserted-by":"crossref","unstructured":"A.B. Lassman, K. Hoang-Xuan, Mei-Yin, et al., Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors, vol 40, 2022. (https:\/\/doi.org\/10).","DOI":"10.1200\/JCO.21.02543"},{"issue":"10","key":"10.1016\/j.jcpo.2024.100476_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2024.100476_bib9","doi-asserted-by":"crossref","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol."},{"issue":"33","key":"10.1016\/j.jcpo.2024.100476_bib10","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.jcpo.2024.100476_bib11","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.3390\/cancers15133274","article-title":"Evaluation of RANO criteria for the assessment of tumor progression for lower-grade gliomas","volume":"15","author":"Raman","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jcpo.2024.100476_bib12","article-title":"Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: a retrospective cohort study","volume":"55","author":"Vera","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jcpo.2024.100476_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient experience captured by quality-of-life measurement in oncology clinical trials","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538324000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538324000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T09:12:14Z","timestamp":1716973934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538324000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":13,"alternative-id":["S2213538324000109"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100476","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100476"}}